Previous 10 | Next 10 |
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress PR Newswire New Data to be Presented for ROCTAVIAN fr...
2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...
2023-06-07 08:55:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Navigating the turbulent waters in the biotech space is no mean feat. With the sector’s inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market ...
2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...
2023-05-15 06:29:07 ET Summary We put BridgeBio Pharma, Inc. in the spotlight for the first time since last summer as the company continues to have buyout speculation around it. BridgeBio also has had some positive recent trial developments and executed a needed capital raise in M...
2023-05-06 16:00:00 ET "Health Care has generated the strongest earnings growth of sectors historically....," the health care team writes. "An aging population is also a secular tailwind for the sector." Regarding current valuations, they added, "pharma trades at a near-record d...
BioMarin to Participate in Bank of America 2023 Health Care Conference PR Newswire SAN RAFAEL, Calif. , May 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller , Executive Vice President, Chief Financial Offi...
2023-04-26 21:05:20 ET Biomarin Pharmaceutical, Inc. (BMRN) Q1 2023 Earnings Conference Call April 26, 2023, 16:30 ET Company Participants Traci McCarty - Group VP, IR Jean-Jacques Bienaime - Chairman & CEO Jeffrey Ajer - Chief Commercial Officer Henry Fu...
2023-04-26 18:21:11 ET The following slide deck was published by BioMarin Pharmaceutical Inc. in conjunction with their 2023 Q1 earnings call. For further details see: BioMarin Pharmaceutical Inc. 2023 Q1 - Results - Earnings Call Presentation
2023-04-26 16:06:23 ET BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q1 Non-GAAP EPS of $0.60 beats by $0.20 . Revenue of $596.4M (+14.8% Y/Y) beats by $26.01M . Growth of VOXZOGO ® Accelerated with Rapid Uptake in Japan and Brazil ...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...